[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"malignant-pleural-effusions-mpe\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:malignant-pleural-effusions-mpe":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,42,68,91,116,136,167,188],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100644610","xuan-yin-ning-plus-bevacizumab-for-malignant-pleural-effusion-100644610",false,"NCT07670338","Xuan Yin Ning Plus Bevacizumab for Malignant Pleural Effusion","A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study of Xuan Yin Ning Formula Combined With Intrapleural Injection of Bevacizumab for the Treatment of Malignant Pleural Effusion.","XYN-Bev MPE","Inclusion Criteria:\n\n* Patients with advanced non-squamous non-small cell lung cancer who have failed at least first-line systemic therapy;\n* Presence of unilateral pleural effusion confirmed as malignant by pathology or cytology, with at least moderate volume requiring drainage (moderate pleural effusion defined as: supine ultrasound examination showing pleural effusion ≥3 cm, or sitting ultrasound examination showing pleural effusion ≥4 cm,accompanied by clinical symptoms such as chest tightness and dyspnea);\n* Age 18-75 years;\n* ECOG performance status 0-2;\n* Traditional Chinese Medicine (TCM) syndrome differentiation classified as Xuanyin (suspension fluid) with fluid retention in the chest and hypochondrium;\n* Expected survival of at least 3 months;\n* Voluntarily signed informed consent before treatment;\n* No contraindications to chest tube placement for drainage;\n* Adequate major organ function, including:\n\n  1. Complete blood count:\n\n     White blood cell count ≥ 4.0×10⁹\u002FL Absolute neutrophil count ≥ 1.5×10⁹\u002FL Platelet count ≥ 100×10⁹\u002FL Hemoglobin ≥ 90 g\u002FL\n  2. Blood biochemistry:\n\n     Total bilirubin ≤ 1.5×ULN ALT ≤ 2.5×ULN, AST ≤ 2.5×ULN Serum creatinine ≤ 1.5×ULN, or creatinine clearance ≥ 50 mL\u002Fmin (Cockcroft-Gault formula)\n  3. Coagulation function:\n\n     International normalized ratio (INR) ≤ 1.5×ULN Activated partial thromboplastin time (APTT) ≤ 1.5×ULN\n  4. Blood glucose: within normal range, or diabetic patients under treatment with stable blood glucose control;\n* Female subjects of childbearing potential must have a negative serum pregnancy test within 72 hours before starting study drug administration, and must use effective contraception (e.g., intrauterine device, contraceptive pills, or condoms) during the study period and for at least 3 months after the last dose. -Male subjects with a partner of childbearing potential must use effective contraception during the study period and for 3 months after the last dose;\n* Good subject compliance, able to follow up for efficacy and adverse events\u002Freactions as required by the protocol.\n\nExclusion Criteria:\n\n* The location of pleural effusion is unsuitable for drainage, or the patient would not benefit from intrapleural drug administration (e.g., severe loculation\u002Fseptation);\n* Other contraindications to indwelling chest tube placement;\n* Pleural effusion with active infection;\n* Prior history of ipsilateral chest tube drainage and intrapleural anti-tumor drug therapy or pleurodesis;\n* Prior history of empyema or chylothorax;\n* Participation in another clinical trial within 4 weeks before signing informed consent;\n* Known allergy to any component of the study drugs;\n* Severe bleeding tendency or active bleeding;\n* Uncontrolled severe hypertension;\n* Recent (within 3 months) thromboembolic events, such as deep vein thrombosis, pulmonary embolism, cerebral infarction, etc.;\n* Prior severe adverse reactions to intravenous bevacizumab, such as severe proteinuria, gastrointestinal perforation, hypertensive crisis, etc.;\n* Severe cardiac, hepatic, or renal insufficiency;\n* Pregnant or breastfeeding women;\n* Subjects with other active infectious diseases in the acute phase;\n* Any other factors that, in the investigator's judgment, may lead to premature termination of the study, such as other serious diseases (including psychiatric disorders) requiring concomitant treatment, alcoholism, drug abuse, family or social factors that may affect the subject's safety or compliance.","ALL","18 Years","75 Years",{"count":21,"type":22},308,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to determine whether the Xuanyin Ning Formula combined with intrapleural injection of bevacizumab via chest tube drainage is effective in treating malignant pleural effusion. It will also evaluate the safety of this combination therapy. The main questions it aims to answer include:\n\nDoes the Xuanyin Ning Formula combined with intrapleural injection of bevacizumab via chest tube drainage improve the objective response rate (ORR) of pleural effusion in patients with malignant pleural effusion? Does this combination therapy affect the duration of response (DoR), progression-free survival (PFS), overall survival (OS), degree of dyspnea, quality of life, and Traditional Chinese Medicine (TCM) pattern\u002Fsyndrome evaluation in patients with malignant pleural effusion?\n\nParticipants will:\n\nReceive intrapleural injection of bevacizumab via chest tube drainage, and take either Xuanyin Ning Formula or placebo granules daily for 8 weeks.\n\nUndergo ultrasound assessment of pleural effusion at 2, 4, 8, and 12 weeks after the first intrapleural injection during closed chest drainage, followed by ultrasound assessments every 3 months (±7 days) until pleural effusion progression.",[28],"Malignant Pleural Effusions (Mpe)","NOT_YET_RECRUITING","2026-06-29",{"date":32,"type":33},"2026-07-01","ACTUAL",{"date":35,"type":22},"2026-06-01",{"date":37,"type":22},"2028-09-01",{"name":39,"class":40},"Shanghai Chest Hospital","OTHER",7,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":67},"100643205","ex-vivo-drug-response-profiling-and-outcome-prediction-in-lung-adenocarcinoma-100643205","NCT07636252","Ex Vivo Drug Response Profiling and Outcome Prediction in Lung Adenocarcinoma","Inclusion Criteria:\n\n* Presence of pleural effusion in patient with a diagnosis of a lung cancer or suspected to be diagnosed with lung cancer according to their CT imaging, who are in need for pleural effusion drainage due to shortness of breath, and are willing to donate effusion for ex-vivo drug sensitivity testing.\n* Patient's written informed consent present.\n* Ability to understand the nature of the trial and the trial related procedures and to comply with them.\n\nExclusion Criteria:\n\n* negative cytology for malignancy in the last 6 months",{"count":49,"type":22},400,"OBSERVATIONAL","This observational study evaluates if ex-vivo lung cancer drug sensitivity testing results correlate with the driver mutations found by genetic sequencing and if it can predict treatment response.",[53,28],"Lung Adenocarcinoma",[55],"Drug sensitivity testing, malignant pleural effusion, lung cancer","RECRUITING","2026-06-18",{"date":59,"type":33},"2026-06-23",{"date":61,"type":33},"2023-06-14",{"date":63,"type":22},"2030-01-01",{"name":65,"class":66},"Sheba Medical Center","OTHER_GOV",1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":75,"targetDuration":4,"studyType":23,"phases":77,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":67},"100642326","phase-2-a-phase-ii-study-to-evaluate-jmkx000197-injection-versus-cisplatin-in-the-treatment-of-malignant-pleural-effusion-100642326","NCT07649369","A Phase II Study to Evaluate JMKX000197 Injection Versus Cisplatin in the Treatment of Malignant Pleural Effusion","A Randomized, Controlled, Double-Blind, Multi-center Phase II Study to Evaluate JMKX000197 Injection Versus Cisplatin in the Treatment of Malignant Pleural Effusion","Inclusion Criteria:\n\n* Participants with advanced solid tumors diagnosed by histopathology or cytopathology.\n* Moderate to large pleural effusions require intervention.\n* ECOG performance status: 0 to 2.\n* Life expectancy ≥ 3 months\n* Adequate organ function.\n* The serum pregnancy test of female participants of childbearing potential should be negative within 7 days prior to enrollment and must not be breastfeeding. With a fertile female\u002Fmale must agree to use medically accepted non-pharmacological contraception during the study and for 6 months after the last dose.\n\nExclusion Criteria:\n\n* Bilateral pleural effusion or concurrent peritoneal effusion, or concurrent pericardial effusion.\n* Pleural effusion is either encapsulated or severely separated; Or merge with chylothorax; Or combined with infectious pleural effusion.\n* Known allergies to the study drug or its excipient components.\n* Have participated in other clinical trials within 28 days prior to randomization.\n* Major surgery within 28 days prior to randomization.\n* Central nervous system metastatic disease, leptomeningeal disease, or cord compression.\n* Clinical unstable or uncontrolled concomitant cardiovascular, pulmonary, hepatic, renal or seizures diseases.\n* Active infections that require systemic treatment.\n* Have a history of organ transplantation.\n* Any further condition which, in the opinion of the Investigator, the participant is not suitable in the present study.",{"count":76,"type":22},120,[78],"PHASE2","This study aims to evaluate the efficacy and safety of intrapleural JMKX000197 compared with intrapleural cisplatin in patients with malignant pleural effusion.",[28],"2026-06-14",{"date":83,"type":33},"2026-06-16",{"date":85,"type":22},"2026-08-17",{"date":87,"type":22},"2028-08-14",{"name":89,"class":90},"Shanghai Jeyou Pharmaceutical Co., Ltd.","INDUSTRY",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":97,"targetDuration":4,"studyType":23,"phases":99,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":67},"100618533","phase-1-first-in-human-expanded-cohort-study-of-intrapleural-administration-of-toluenesulfonamide-in-patients-with-malignant-pleural-effusion-100618533","NCT07332858","First-in-Human Expanded Cohort Study of Intrapleural Administration of TolueneSulfonamide in Patients With Malignant Pleural Effusion","Inclusion Criteria:\n\n1. Age between 18 and 75 years (inclusive) at the time of signing the informed consent form.\n2. Histologically or cytologically confirmed malignant pleural effusion, with the primary tumor diagnosed as non-small cell lung cancer (NSCLC).\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, with an expected survival of at least 3 months.\n4. Presence of dyspnea symptoms.\n5. No prior local thoracic treatment within 1 month before enrollment, including intrapleural drug administration or thoracic radiotherapy (diagnostic thoracentesis is permitted).\n6. Except for the subject's current stable systemic anti-tumor therapy, any other ongoing tumor-related treatments must be suspended or discontinued after evaluation by the investigator to ensure they do not interfere with the assessment of PTS treatment.\n7. Fully understands the study objectives and procedures, agrees to participate in the study, and provides written informed consent.\n\nExclusion Criteria:\n\n1. History of allergy or hypersensitivity to PTS or any of its excipients.\n2. Presence of uncontrolled intrapleural infection or severe loculated pleural effusion that is difficult to manage.\n3. Participation in another interventional clinical study within 3 months prior to enrollment (diagnostic studies are excluded).\n4. Severe organ dysfunction, including but not limited to coagulation disorders, congestive heart failure, malignant arrhythmias, coronary artery disease requiring long-term medication, valvular heart disease, myocardial infarction, or refractory hypertension; severe cardiac, hepatic, or renal insufficiency, or active bleeding or thrombotic risk.\n5. Presence of uncontrolled infectious wounds.\n6. Pregnant or breastfeeding women.\n7. Any other condition that, in the investigator's judgment, makes the subject unsuitable for participation in this study.\n8. Criteria for withdrawal from the study.",{"count":98,"type":22},105,[100,78],"PHASE1","This study aims to evaluate the safety of intrapleural injection of TolueneSulfonamide in patients with malignant pleural effusion and to explore its potential effectiveness.",[28,103],"Non Small Cell Lung Cancer",[105,106],"Malignant Pleural Effusion","Para-toluenesulfonamide","2026-05-14",{"date":109,"type":33},"2026-05-15",{"date":111,"type":33},"2026-04-24",{"date":113,"type":22},"2028-10-30",{"name":115,"class":40},"Gang Hou",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":23,"phases":124,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":67},"100602235","impact-of-pleural-manometry-on-the-assessment-and-treatment-of-malignant-pleural-effusion-a-pilot-clinical-trial-100602235","NCT07120867","Impact of Pleural Manometry on the Assessment and Treatment of Malignant Pleural Effusion: A Pilot Clinical Trial","Inclusion Criteria:\n\n* Histologically confirmed cancer and symptomatic patient with at least one of the following:\n\n  * Malignant pleural effusion confirmed by cytology.\n  * Recurrent exudative pleural effusion without an alternative diagnosis in the context of confirmed extrapleural cancer.\n  * Pleural effusion associated with hypermetabolic pleural thickening suggestive of malignant pleural effusion.\n\nExclusion Criteria:\n\n* Radiological evidence of non-expandable lung\n* Life expectancy \\\u003C1 month (LENT score: high risk)\n* Previous ipsilateral lobectomy or pneumonectomy\n* Previous ipsilateral chemotherapy or radiotherapy\n* Presence of infected pleural effusion\n* Patient preference for tunneled pleural catheter placement\n* Pregnancy\n* Thrombocytopenia or coagulopathy\n* Contraindication to general anesthesia or sedation",{"count":123,"type":22},95,[25],"The goal of this clinical trial is to find out if performing a pleural fluid drainage (thoracentesis) together with the measurement of pressure inside the chest (pleural manometry) during the same procedure can help doctors choose the best treatment for each patient with malignant pleural effusion.The main questions it aims to answer are:\n\n* Is the use of pleural manometry associated with a higher success rate in managing malignant pleural effusion through pleurodesis?\n* Can the use of pleural manometry help guide optimal therapeutic decision-making in malignant pleural effusion?\n\nResearchers will compare the success of the chosen treatment in patients who undergo pleural manometry to those who do not, to see if pleural manometry helps improve treatment outcomes for malignant pleural effusion.\n\nParticipants will:\n\n* Receive treatment according to the hospital's standard clinical practice for managing malignant pleural effusion.\n* If assigned to the manometry group, they will undergo pleural manometry during their first thoracentesis.\n* If the manometry results suggest that the lung can fully expand, they will be referred for pleurodesis-just as patients in the non-manometry group are.\n* If the manometry results suggest that the lung cannot fully expand, pleurodesis will not be recommended due to the high risk of failure. Instead, placement of a tunneled pleural catheter will be advised to help control symptoms.",[28],"2025-08-06",{"date":129,"type":33},"2025-08-13",{"date":131,"type":33},"2023-07-28",{"date":133,"type":22},"2026-07",{"name":135,"class":40},"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":23,"phases":146,"briefSummary":147,"conditions":148,"keywords":152,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":67},"100589846","armstrong---air-entrainment-vs-standard-treatment-in-non-expandable-lung-100589846","NCT06959719","ARMSTRONG - Air entRainMent vS sTandard tReatment in nOn-expandable luNG","Air Entrainment vs. Standard Treatment in Non-Expandable Lung With Persistent Pleural Effusion: A Randomised Controlled Double-Blind Trial","ARMSTRONG","Inclusion Criteria:\n\n* Adults aged 18 years or older with a suspected or confirmed diagnosis of NEL and persistent pleural effusion.\n* Patients who are scheduled for pleural effusion drainage as part of their standard care.\n* Ability to adequately understand verbal or written information in English and provide informed consent in English.\n\nExclusion Criteria:\n\n* Patients with a history of pleurodesis or other procedures that may affect pleural dynamics.\n* Patients with active infections or other acute medical conditions that could interfere with the study.\n* Patient with multifactorial pain and high baseline score pain defined as VAS \\>= 5\n* Patients requiring IPC\n* Individuals with known contraindications to pleural drainage or air entrainment.\n* Patients who cannot provide informed consent in English, do not adequately understand verbal or written information in English or have special communication needs.",{"count":145,"type":22},41,[25],"This is a randomised controlled trial evaluating whether controlled air introduction into pleural space (air entrainment) during pleural effusion drainage reduces pain, improves patient satisfaction, and facilitates more effective drainage in patients with non-expandable lung (NEL).\n\nNEL lung is a common complication in patients with malignant or chronic pleural effusions, where the lung fails to fully re-expand after fluid removal due to pleural disease or fibrosis. In these patients, drainage often creates excessive negative pressure within the pleural cavity, leading to pain, vasovagal episodes, early termination of drainage, and the need for repeated procedures.\n\nThis study investigates a simple, safe, and low-cost intervention using a standard 3-way tap attached to the drainage system. By intermittently opening the tap to atmospheric air during drainage, air enters the pleural cavity in a controlled fashion, reducing negative pressure and potentially reducing pain, improving drainage tolerance, and minimising the need for repeated procedures.\n\nPleural effusion drainage is a common procedure in patients with advanced malignancy or chronic pleural disease. In patients with NEL, fluid removal creates a vacuum effect within the pleural space due to the inability of the lung to fully re-expand. This negative pressure is a key driver of severe procedural pain, vasovagal symptoms, and premature cessation of drainage. It may also necessitate multiple drainage procedures over a short period.\n\nCurrently, there are limited strategies to mitigate this problem, often relying on stopping the procedure prematurely or on analgesia, which does not address the underlying cause.\n\nThis trial evaluates the introduction of atmospheric air into the pleural space during drainage as a pragmatic, low-cost solution. The technique uses standard equipment - a 3-way tap - allowing air to be introduced safely and intermittently during drainage to reduce the vacuum effect.\n\nPatients undergoing therapeutic pleural drainage with an indwelling catheter or chest drain will be randomised in a 2:1 ratio to:\n\nStandard drainage care (control group)\n\nDrainage with intermittent controlled air introduction (intervention group)\n\nAir entrainment will be performed by briefly opening the 3-way tap to atmospheric air during drainage up to five times, based on patient discomfort and operator discretion. This aims to equalise pleural pressures, reduce pain, and improve drainage outcomes.\n\nRandomisation is weighted 2:1 towards the intervention group to maximise the number of patients who may benefit, following favourable preliminary data. Both patients and outcome assessors will be blinded to group allocation.\n\nOutcomes collected\n\nPrimary Outcomes:\n\nPatient-reported pain scores during drainage - Pain will be assessed using the Visual Analogue Scale (VAS), ranging from 0 to 10 cm, where 0 indicates \"no pain\" and 10 indicates \"worst imaginable pain.\" Higher scores represent a worse outcome.\n\nSecondary Outcomes:\n\nVolume of pleural fluid drained Number of pleural drainage procedures required Time interval between drainage procedures Incidence of complications (e.g., pneumothorax, re-expansion pulmonary oedema, infection) Reasons for incomplete drainage, including the presence and characteristics of non-expandable lung Patient-reported satisfaction with the drainage procedure",[149,150,151,28],"Non-expandable Lung","Trapped Lung","Pleural Effusion",[153,154,155,156,157],"air entrainment","trapped lung","non-expandable lung (NEL)","pleural effusion","malignant pleural effusion","2025-05-04",{"date":160,"type":33},"2025-05-07",{"date":162,"type":33},"2025-04-14",{"date":164,"type":22},"2026-10-30",{"name":166,"class":40},"Cambridge University Hospitals NHS Foundation Trust",{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":174,"targetDuration":4,"studyType":23,"phases":176,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":67},"100572957","phase-1-a-phase-ib-study-of-jmkx000197-injection-in-the-treatment-of-malignant-pleural-effusion-100572957","NCT06740019","A Phase Ib Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion","A Phase Ib, Open Label, Multicenter Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion","Inclusion Criteria:\n\n1. The participant voluntarily joined the study, signed an informed consent form, and had good compliance.\n2. Age ≥ 18 years and ≤ 75 years old, regardless of gender.\n3. Participants with advanced solid tumors diagnosed by histopathology or cytopathology.\n4. Malignant pleural effusion confirmed by histopathology or cytopathology or clinically diagnosed as moderate or above and requiring drainage.\n5. Eastern Cooperative Oncology Group (ECOG) performance status: 0 to 2.\n6. Life expectancy of at least 3 months.\n7. Adequate organ function.\n8. Female participants of childbearing potential should agree to use contraception to prevent pregnancy until 6 months after discontinuation of JMKX000197. The serum pregnancy test result should be negative 7 days before enrollment and must be a non-lactating participant. Male participants must agree to use effective contraception during the study and for 6 months after discontinuation of JMKX000197.\n\nExclusion Criteria:\n\n1. Bilateral pleural effusion or concurrent peritoneal effusion, or concurrent pericardial effusion.\n2. Pleural effusion is either encapsulated or severely separated; Or merge with chylothorax; Or combined with infectious pleural effusion.\n3. Have used interferon gene stimulating factor (STING) agonists for pleural perfusion。\n4. Known allergies to the study drug or its excipient components.\n5. Have participated in other clinical trials within 28 days prior to randomization.\n6. Major surgery within 28 days prior to randomization.\n7. Central nervous system metastatic disease, leptomeningeal disease, or cord compression.\n8. Clinical unstable or uncontrolled concomitant cardiovascular, pulmonary, hepatic, renal or seizures diseases.\n9. Uncontrollable systemic infections (viruses, bacteria, fungi), including but not limited to positive HBsAg and HBV DNA, positive HCV RNA, positive HIV antibody test or combined infections within the first 28 days of randomization and require systemic anti-infective treatment.\n10. Have a history of organ transplantation.\n11. Any further condition which, in the opinion of the Investigator, the participant is not suitable in the present study.",{"count":175,"type":22},30,[100],"A Phase Ib Study to Evaluate the Safety, Tolerance, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion",[28],"2025-04-01",{"date":181,"type":33},"2025-04-04",{"date":183,"type":33},"2024-12-28",{"date":185,"type":22},"2026-11",{"name":187,"class":90},"Jemincare",{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":23,"phases":197,"briefSummary":199,"conditions":200,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":67},"100573116","early-phase-1-the-outcome-of-inserting-intercostal-tube-or-pleurodesis-for-malignant-pleural-effusion-100573116","NCT06742099","The Outcome of Inserting Intercostal Tube or Pleurodesis for Malignant Pleural Effusion","Outcome of Intercostal Tube Insertion and Pleurodesis for Malignant Pleural Effusion","Inclusion Criteria:\n\n* All patients presented with malignant pleural effusion to Assiut University Hospital regardless of sex and age\n\nExclusion Criteria:\n\n* All patients presented with pleural effusion other than malignant pleural effusion, including patients with debilitating diseases and terminal patients.",{"count":196,"type":22},20,[198],"EARLY_PHASE1","Approximately half of all patients with metastatic cancer develop a malignant pleural effusion which is likely to lead to a significant reduction in quality of life secondary to symptoms such as dyspnoea and cough. The aim of pleurodesis in these patients is to prevent re-accumulation of the effusion and thereby of symptoms,and avoid the need for repeated hospitalization for thoracocentesis. Numerous clinical studies have been performed to try to determine the optimal pleurodesis strategy, and synthesis of the available evidence should facilitate this. The treatment of MPE is aimed at palliating symptoms since no intervention has been shown to improve survival in this population and since survival is generally limited in cancers that have spread to the pleural space. In this palliative setting, only patients symptomatic from their MPE should be submitted to further intervention. As well, further interventions in symptomatic patients should be limited to those patients who have experienced symptomatic improvement following initial therapeutic thoracentesis. The two main treatment approaches to MPE are to obliterate the pleural space via a pleurodesis procedure or to chronically drain the pleural cavity with Intercostal tube. The aims of this review were to ascertain the optimal procedure in cases of malignant pleural effusion in terms of patients' quality of life post procedure, recurrence of effusion.",[28],"2024-12-17",{"date":203,"type":33},"2024-12-19",{"date":205,"type":22},"2024-12-30",{"date":207,"type":22},"2025-09-30",{"name":209,"class":40},"Assiut University"]